With a team led by Dr. Ulrich Jork, the business and commercial law firm of Heuking Kühn Lüer Wojtek advised Prof. Dr. Heinz-Herbert Fiebig, sole shareholder of Oncotest, on the sale of his shares to Charles River Laboratories International. The transaction total is EUR 34 million plus a potential additional payment of EUR 2 million based on future performance of the company.
Oncotest, founded in 1992, is a service provider for the pharmaceutical industry to test antitumor drugs. An extensive collection of more than 400 patient-derived xenograft tumor models is used for in vivo pharmacology services. Oncotest offers (colony assay and in vivo) studies on permanent cell lines or human tumor xenografts. For target-oriented approaches, tumor models are selected based on their patterns of expression (gene chip, tissue microarray, flow cytometry). In addition, in silico analysis is used to assess potential effects of substances.
Integrated with Charles River Laboratories’ broad portfolio, the acquisition will create a leading provider for the validation of novel cancer therapies. Oncotest GmbH will become part of Charles River Laboratories’ “In Vivo Discovery” business in the future.
Counsel to Prof. Dr. Heinz-Herbert Fiebig, sole shareholder of Oncotest GmbH
Heuking Kühn Lüer Wojtek:
Dr. Ulrich Jork,
Marcel Greubel (both Lead, both M&A), both Munich,
Dr. Marc Scheunemann (M&A, Tax),
Christoph Nöhles (Real Estate),
Astrid Luedtke (IP), all Düsseldorf